A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Phase 3

Recruiting

• Conditions: Breast Cancer
• Interventions: Drug: Inavolisib; Drug: Fulvestrant; Drug: Alpelisib

• Registration Number: NCT05646862
• Lead Sponsor: Hoffmann-La Roche

Brief Summary

This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulvestrant in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) -negative, PIK3CA-mutated, locally advanced (LA) or metastatic breast cance...

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations
|
Related News

Study Timeline

• Study First Submitted: 2022-12-02
• Study First Submitted QC: 2022-12-02
• Study First Posted: 2022-12-12
• Study Start: 2023-06-07
• Status Verified: 2024-11
• Last Update Submitted: 2024-11-22
• Last Update Posted: 2024-11-25
• Primary Completion: 2029-03-30
• Study Completion: 2029-03-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

• If pre/perimenopausal women and men treatment with luteinizing hormone-releasing hormone (LHRH) agonist therapy beginning at least 2 weeks prior to Day 1 of Cycle 1
• Histologically or cytologically confirmed adenocarcinoma of the breast that is locally advanced or metastatic and is not amenable to surgical or radiation therapy with curative intent
• Documented HR +/ HER2- tumor according to American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines
• Confirmation of biomarker eligibility: detection of specified mutation(s) of PIK3CA via specified test
• Disease progression after or during treatment with a combination of CDK4/6i and endocrine therapy: <= 2 prior lines of systemic therapy in mBC setting; CDK4/6i based therapy does not need to be the last one received prior study entry; one line of chemotherapy in mBC setting allowed
• Measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
• Participants for whom endocrine-based therapy is recommended and treatment with cytotoxic chemotherapy is not indicated at time of entry into the study, as per national or local treatment guidelines
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
• Life expectancy of > 6 months
• Adequate hematologic and organ function prior to initiation of study treatment

Read More

Exclusion Criteria

• Metaplastic breast cancer
• Prior treatment in locally advanced or metastatic setting with any PI3K, AKT, or mTOR inhibitor or any agent whose mechanism of action is to inhibit the PI3K/-AKT/-mTOR pathway
• Participant who relapsed with documented evidence of progression > 12 months from completion of adjuvant CDK4/6i based therapy with no treatment for metastatic disease
• Pregnant, lactating, or breastfeeding, or intending to become pregnant during the study or at least 60 days after the final dose of study treatment
• Type 2 diabetes requiring ongoing systemic treatment at the time of study entry; or any history of Type 1 diabetes
• Inability or unwillingness to swallow pills
• Malabsorption syndrome or other condition that would interfere with enteral absorption
• Any history of leptomeningeal disease or carcinomatous meningitis
• Known and untreated, or active central nervous system (CNS) metastases. Participants with a history of treated CNS metastases are eligible if they meet specific certain criteria
• Known active, systemic infection at study enrollment, or any major episode of infection requiring treatment with intravenous antibiotics or hospitalization within 7 days prior to Day 1 of Cycle 1
• Any concurrent ocular or intraocular condition that, in the opinion of the investigator, would require medical or surgical intervention during the study period to prevent or treat vision loss that might result from that condition
• Active inflammatory or infectious conditions in either eye or history of idiopathic or autoimmune-associated uveitis in either eye
• Requirement for daily supplemental oxygen
• Symptomatic active lung disease, including pneumonitis
• History of or active inflammatory bowel disease
• Any active bowel inflammation
• Clinically significant and active liver disease, including severe liver impairment, viral or other hepatitis, current alcohol abuse, or cirrhosis
• Participants with known human immunodeficiency virus infection that meet specific criteria
• Investigational drug(s) within 4 weeks before randomization or within 5 half-lives of the investigational drug(s), whichever is longer
• History of other malignancy within 5 years prior to screening, except for cancers with very low risk of recurrence
• Chronic therapy of >= 10 mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids or immunosuppressants for a chronic disease
• Allergy or hypersensitivity to components or excipients of the inavolisib, fulvestrant, or alpelisib formulations
• History of severe cutaneous reactions like Stevens-Johnson Syndrome, Erythema Multiforme, Toxic Epidermal Necrolysis, or Drug Reaction with Eosinphilia and Systemic Symptoms
• Active ongoing osteonecrosis of the jaw

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Inavolisib + Fulvestrant	Inavolisib	Participants will be administered the treatments as outlined in the interventions section.
Inavolisib + Fulvestrant	Fulvestrant	Participants will be administered the treatments as outlined in the interventions section.
Alpelisib + Fulvestrant	Fulvestrant	Participants will be administered the treatments as outlined in the interventions section.
Alpelisib + Fulvestrant	Alpelisib	Participants will be administered the treatments as outlined in the interventions section.

Primary Outcome Measures

Name	Time	Method
Blinded Independent Central Review (BICR)-Assessed Progression Free Survival (PFS)	From randomization until disease progression or death due to any cause (up to approximately 64 months)

Secondary Outcome Measures

Name	Time	Method
TTCD in Physical Functioning	Day 1 of Cycles 1 and 2 and beyond, 30-day safety follow up visit, post-treatment tumor assessment follow-up with PRO collection and survival follow up visit (up to approximately 85 months). Each cycle is 28 days.
Percentage of Participants with Adverse Events	Day 1 until 30 days after the final dose of study treatment (up to approximately 85 months)
Plasma Concentration of Inavolisib at Specified Timepoints	Day 1 and 15 of Cycle 1, and Day 1 of Cycles 2 and 3. Each cycle is 28 days.
TTCD in Global Health Status/Quality of Life (QOL)	Day 1 of Cycles 1 and 2 and beyond, 30-day safety follow up visit, post-treatment tumor assessment follow-up with PRO collection and survival follow up visit (up to approximately 85 months). Each cycle is 28 days.
BICR-Assessed Duration of Response (DOR)	From CR or PR until disease progression or death due to any cause (up to approximately 64 months)
Time to Confirmed Deterioration (TTCD) in Pain	Day 1 of Cycles 1 and 2 and beyond, 30-day safety follow up visit, post-treatment tumor assessment follow-up with PRO collection and survival follow up visit (up to approximately 85 months). Each cycle is 28 days.
Overall survival (OS)	From randomization until death due to any cause (up to approximately 85 months)
BICR-Assessed Overall Response Rate (ORR)	Up to approximately 64 months
BICR-Assessed Best Overall Response (BOR)	Up to approximately 64 months
BICR-Assessed Clinical Benefit Rate (CBR)	Up to approximately 64 months
TTCD in Role Functioning	Day 1 of Cycles 1 and 2 and beyond, 30-day safety follow up visit, post-treatment tumor assessment follow-up with PRO collection and survival follow up visit (up to approximately 85 months). Each cycle is 28 days.

Trial Locations

Locations (208)

Massachusetts General Hospital; 🇺🇸 Boston, Massachusetts, United States

Instituto D'Or de Pesquisa e Ensino; 🇧🇷 Rio de Janeiro, RJ, Brazil

Banner MD Anderson Cancer Center; 🇺🇸 Gilbert, Arizona, United States

Marin Cancer Care Inc; 🇺🇸 Greenbrae, California, United States

Cancer Blood and Specialty Clinic; 🇺🇸 Los Alamitos, California, United States

Los Angeles Cancer Network; 🇺🇸 Los Angeles, California, United States

University of California, Irvine Medical Center; 🇺🇸 Orange, California, United States

Eastern CT Hematology and Oncology Associates; 🇺🇸 Norwich, Connecticut, United States

Cancer Care Centers of Brevard; 🇺🇸 Rockledge, Florida, United States

UC Davis Comprehensive Cancer Center; 🇺🇸 Sacramento, California, United States

Rocky Mountain Cancer Centers; 🇺🇸 Denver, Colorado, United States

Cleveland Clinic Florida; 🇺🇸 Weston, Florida, United States

Grady Health System; 🇺🇸 Atlanta, Georgia, United States

Midtown West Medical; 🇺🇸 Atlanta, Georgia, United States

Emory University Hospital; 🇺🇸 Atlanta, Georgia, United States

Karmanos Cancer Institute.; 🇺🇸 Detroit, Michigan, United States

Cancer & Hematology Centers of Western Michigan; 🇺🇸 Grand Rapids, Michigan, United States

Minnesota Oncology Hematology; 🇺🇸 Saint Paul, Minnesota, United States

Winship Cancer Institute at Emory Saint Joseph's Hospital; 🇺🇸 Atlanta, Georgia, United States

University of Louisville Hospital; The James Graham Brown Cancer Center; 🇺🇸 Louisville, Kentucky, United States

MD Anderson Cancer Center at Cooper; 🇺🇸 Camden, New Jersey, United States

Novant Health Presbyterain Medical Center; 🇺🇸 Charlotte, North Carolina, United States

Novant Health Forsyth Medical Center; 🇺🇸 Winston-Salem, North Carolina, United States

St. Lukes Hospital and Health Network; 🇺🇸 Bethlehem, Pennsylvania, United States

Consultants in Medical Oncology and Hematology; 🇺🇸 Broomall, Pennsylvania, United States

Gabrail Cancer Center; 🇺🇸 Canton, Ohio, United States

Asante Rogue Regional Medical Center; 🇺🇸 Medford, Oregon, United States

Juravinski Hospital; 🇨🇦 Hamilton, Ontario, Canada

Abramson Cancer Center Chester County Hospital; Hematology, Medical Oncology; 🇺🇸 West Chester, Pennsylvania, United States

WellSpan Oncology Research; 🇺🇸 York, Pennsylvania, United States

Texas Oncology West; 🇺🇸 Amarillo, Texas, United States

Texas Oncology - Dallas Presbyterian Hospital; 🇺🇸 Dallas, Texas, United States

Texas Tech University Health Sciences Center; Department of Internal Medicine; 🇺🇸 El Paso, Texas, United States

Texas Oncology (Flower Mound) - USOR; 🇺🇸 Flower Mound, Texas, United States

The Center for Cancer and Blood Disorders - Fort Worth; 🇺🇸 Fort Worth, Texas, United States

Lumi Research; 🇺🇸 Kingwood, Texas, United States

Texas Oncology McKinney; 🇺🇸 McKinney, Texas, United States

Kadlec Clinic Hematology and Oncology; 🇺🇸 Kennewick, Washington, United States

Fundación CENIT para la Investigación en Neurociencias; 🇦🇷 Buenos Aires, Argentina

Centro Oncologico Korben; Oncology; 🇦🇷 Ciudad Autonoma Buenos Aires, Argentina

Fundacion CORI para la Investigacion y Prevencion del Cancer; 🇦🇷 La Rioja, Argentina

Instituto de Oncología de Rosario; 🇦🇷 Rosario, Argentina

Sanatorio Parque S.A.; 🇦🇷 Rosario, Argentina

Hosp Provincial D. Centenarios; Oncology Dept; 🇦🇷 Rosario, Argentina

CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica; 🇦🇷 San Juan, Argentina

Clinica Viedma S.A.; 🇦🇷 Viedma, Argentina

Campbelltown Hospital; Macarthur Cancer Therapy Centre; 🇦🇺 Campbelltown, New South Wales, Australia

Coffs Harbour Health Campus; 🇦🇺 Coffs Harbour, New South Wales, Australia

Icon Cancer Care Wesley; 🇦🇺 Auchenflower, Queensland, Australia

University of the Sunshine Coast; 🇦🇺 Sippy Downs, Queensland, Australia

Bendigo Cancer Centre; 🇦🇺 Bendigo, Victoria, Australia

Concord Repatriation General Hospital; Concord Cancer Centre; 🇦🇺 Concord, New South Wales, Australia

National Taiwan University Hospital; Oncology; 🇨🇳 Zhongzheng Dist., Taiwan

Kinghorn Cancer Centre; St Vincents Hospital; 🇦🇺 Darlinghurst, New South Wales, Australia

Gosford Hospital; Cancer Care Services; 🇦🇺 Gosford, New South Wales, Australia

Sir Charles Gairdner Hospital; Medical Oncology; 🇦🇺 Perth, Western Australia, Australia

UZ Antwerpen; 🇧🇪 Edegem, Belgium

UZ Gent; 🇧🇪 Gent, Belgium

Cliniques Universitaires St-Luc; 🇧🇪 Bruxelles, Belgium

GHdC Site Notre Dame; 🇧🇪 Charleroi, Belgium

UZ Leuven Gasthuisberg; 🇧🇪 Leuven, Belgium

Clinique Ste-Elisabeth; 🇧🇪 Namur, Belgium

Hospital da Bahia; 🇧🇷 Salvador, BA, Brazil

Instituto D?Or de Pesquisa e Ensino ? Hospital DF STAR; 🇧🇷 Brasilia, DF, Brazil

NUPEC; 🇧🇷 Belo Horizonte, MG, Brazil

Hospital do Cancer de Pernambuco - HCP; 🇧🇷 Recife, PE, Brazil

Instituto D?Or de Pesquisa e Ensino ? Hospital Esperança Recife; 🇧🇷 Recife, PE, Brazil

Vencer Oncoclínica - Centro de Pesquisa do Piauí; 🇧🇷 Teresina, PI, Brazil

Santa Casa de Misericordia de Porto Alegre; 🇧🇷 Porto Alegre, RS, Brazil

Hospital Sao Lucas - PUCRS; 🇧🇷 Porto Alegre, RS, Brazil

Hospital de Base de Sao Jose do Rio Preto; 🇧🇷 Sao Jose do Rio Preto, SP, Brazil

Hospital Santa Cruz / Centro de Oncologia D'Or; 🇧🇷 Curitiba, PR, Brazil

Liga Norte Riograndense Contra O Câncer; 🇧🇷 Natal, RN, Brazil

Hospital Sírio-Libanês; 🇧🇷 Sao Paulo, SP, Brazil

Tom Baker Cancer Centre-Calgary; 🇨🇦 Calgary, Alberta, Canada

Cross Cancer Institute; 🇨🇦 Edmonton, Alberta, Canada

BC Cancer ? Vancouver; 🇨🇦 Vancouver, British Columbia, Canada

The Moncton Hospital; 🇨🇦 Moncton, New Brunswick, Canada

Eastern Health - General Hospital; 🇨🇦 St. John's, Newfoundland and Labrador, Canada

The Ottawa Hospital - General Campus; 🇨🇦 Ottawa, Ontario, Canada

CIUSSS de l Est de l Ile de Montreal - Hopital Maisonneuve Rosemont; 🇨🇦 Montreal, Quebec, Canada

Centre Hospitalier de l'Universite de Montreal (CHUM); 🇨🇦 Montreal, Quebec, Canada

Jewish General Hospital; 🇨🇦 Montreal, Quebec, Canada

Hôpital du Sacré-Coeur de Montreal; 🇨🇦 Montreal, Quebec, Canada

The First Hospital of Jilin University; 🇨🇳 Changchun City, China

Sichuan Provincial Cancer Hospital; 🇨🇳 Chengdu, China

The First Affiliated Hospital, Chongqing Medical University; 🇨🇳 Chongqing, China

Guangdong Provincial People's Hospital; Breast; 🇨🇳 Guangzhou City, China

Sun yat-sen University Cancer Center; Internal Medicine of Oncology; 🇨🇳 Guangzhou, China

The Second Affiliated Hospital of Zhejiang University School of Medicine; 🇨🇳 Hangzhou City, China

Sir Run Run Shaw Hospital Zhejiang University; 🇨🇳 Hangzhou City, China

Harbin Medical University Tumor Hospital; Department of Surgery; Pharmacy; 🇨🇳 Harbin, China

Shandong Cancer Hospital; 🇨🇳 Jinan, China

The Second Affiliated Hospital to Nanchang University; 🇨🇳 Nanchang, China

Tianjin Cancer Hospital; Department of Breast Oncology; 🇨🇳 Tianjin, China

Union Hospital Tongji Medical College Huazhong University of Science and Technology; 🇨🇳 Wuhan City, China

Hubei Cancer Hospital; 🇨🇳 Wuhan, China

First Affiliated Hospital of Medical College of Xi'an Jiaotong University; 🇨🇳 Xi'an, China

Jiangsu Cancer Hospital; 🇨🇳 Nanjing City, China

Zhejiang Cancer Hospital; 🇨🇳 Zhejiang, China

Institut Sainte Catherine; 🇫🇷 Avignon, France

Centre Eugene Marquis; Service d'oncologie; 🇫🇷 Rennes, France

Centre Hospitalier de La Cote Basque; Oncologie; 🇫🇷 Bayonne, France

Polyclinique Bordeaux Nord; 🇫🇷 Bordeaux, France

IUCT Oncopole; 🇫🇷 Toulouse, France

Centre Leon Berard; Service Oncologie Medicale; 🇫🇷 Lyon, France

ICM; Medecine B3; 🇫🇷 Montpellier cedex 5, France

Uniklinik RWTH Aachen Klinik für Gynäkologie und Geburtsmedizin; 🇩🇪 Aachen, Germany

Onkologische Schwerpunktpraxis Bielefeld; 🇩🇪 Bielefeld, Germany

Universitätsklinikum Essen; Zentrum Für Frauenheilkunde; 🇩🇪 Essen, Germany

Praxis für Interdisziplinäre Onkologie und Hämatologie GbR; 🇩🇪 Freiburg, Germany

Niels-Stensen-Kliniken Franziskus-Hospital Harderberg GmbH; 🇩🇪 Georgsmarienhütte, Germany

Universitätsmedizin Göttingen Georg-August-Universität; Klinik für Gynäkologie und Geburtshilfe; 🇩🇪 Göttingen, Germany

Mammazentrum Hamburg am Krankenhaus Jerusalem; 🇩🇪 Hamburg, Germany

Medizinische Hochschule Zentrum Frauenheilkunde Abt.Gynäkologische Onkologie; 🇩🇪 Hannover, Germany

Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg; 🇩🇪 Heidelberg, Germany

Brustzentrum Rhein-Ruhr Servicegesellschaft mbH; 🇩🇪 Mönchengladbach, Germany

Klinik & Poliklinik für Frauenheilkunde und Geburtshilfe, Campus Innenstadt; 🇩🇪 München, Germany

St. Vincenz-Krankenhaus GmbH Paderborn Frauen- und Kinderklinik St. Louise; 🇩🇪 Paderborn, Germany

Studienzentrum Onkologie Ravensburg GbR; Onkologie Ravensburg; 🇩🇪 Ravensburg, Germany

A.O. S. Anna e San Sebastiano; Oncologia; 🇮🇹 Caserta, Campania, Italy

IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica; 🇮🇹 Meldola, Emilia-Romagna, Italy

AUSL della Romagna; Dipartimento Oncoematologico - U.O.C. Oncologia; 🇮🇹 Ravenna, Emilia-Romagna, Italy

Irccs Centro Di Riferimento Oncologico (CRO); 🇮🇹 Aviano, Friuli-Venezia Giulia, Italy

Ospedale San Raffaele; Medical Oncology; 🇮🇹 Milano, Lombardia, Italy

Ospedale Di Macerata; Oncologia; 🇮🇹 Macerata, Marche, Italy

ASL AL - Azienda Sanitaria Locale AL; S.C. Oncologia; 🇮🇹 Alessandria, Piemonte, Italy

AOU Città della Salute e della Scienza di Torino; 🇮🇹 Torino, Piemonte, Italy

Humanitas Centro Catanese Di Oncologia; Oncologia Medica; 🇮🇹 Misterbianco (CT), Sicilia, Italy

Ospedale S. Giuseppe; Oncologia; 🇮🇹 Empoli (FI), Toscana, Italy

Ospedale Santa Chiara; Oncologia Medica; 🇮🇹 Trento, Trentino-Alto Adige, Italy

Chulalongkorn Hospital; Medical Oncology; 🇹🇭 Bangkok, Thailand

Kyungpook National University Chilgok Hospital; 🇰🇷 Daegu, Korea, Republic of

National Cancer Center; 🇰🇷 Goyang-si, Korea, Republic of

CHA Bundang Medical Center; 🇰🇷 Gyeonggi-do, Korea, Republic of

Catholic Univ. of Incheon St.Mary's Hospital; 🇰🇷 Incheon, Korea, Republic of

Inha University Hospital; 🇰🇷 Incheon, Korea, Republic of

Korea University Anam Hospital; 🇰🇷 Seoul, Korea, Republic of

Seoul National University Hospital; 🇰🇷 Seoul, Korea, Republic of

Severance Hospital, Yonsei University Health System; 🇰🇷 Seoul, Korea, Republic of

Samsung Medical Center; 🇰🇷 Seoul, Korea, Republic of

Seoul St Mary's Hospital; 🇰🇷 Seoul, Korea, Republic of

Asan Medical Center; 🇰🇷 Seoul, Korea, Republic of

Gangnam Severance Hospital; 🇰🇷 Seoul, Korea, Republic of

Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde; 🇲🇽 Guadalajara, Jalisco, Mexico

Panamerican Clinical Research S.A de C.V.; 🇲🇽 Guadalajara, Jalisco, Mexico

RENATI INNOVATION S.A.P.I. de C.V; 🇲🇽 Guadalajara, Jalisco, Mexico

Health Pharma Professional Research; 🇲🇽 Cdmx, Mexico CITY (federal District), Mexico

COI Centro Oncologico Internacional Santa Fe; 🇲🇽 Ciudad de México, Mexico CITY (federal District), Mexico

OncoMed; Supportive Care; 🇲🇽 Ciudad de México, Mexico CITY (federal District), Mexico

ARKE Estudios Clínicos S.A. de C.V.; 🇲🇽 Ciudad de México, Mexico

Instituto Nacional de Cancerologia; Oncology; 🇲🇽 Mexico City, Mexico

Centrum Onkologii im. Prof. Franciszka ?ukaszczyka; Ambulatorium Chemioterapii; 🇵🇱 Bydgoszcz, Poland

CENEIT Oncologicos; DENTRO DE CONDOMINIO SAN FRANCISCO; 🇲🇽 Mexico City, Mexico

Szpital Morski im.PCK; Oddzial Onkologii Klinicznej, Oddzial Dzienny; 🇵🇱 Gdynia, Poland

Narodowy Instytut Onkologii Odzia? w Gliwicach; Centrum Diagnostyki i Leczenia Chorób Piersi; 🇵🇱 Gliwice, Poland

Przychodnia Lekarska KOMED, Roman Karaszewski; 🇵🇱 Konin, Poland

Szpital Wojewódzki im. Miko?aja Kopernika; Oddzia? Dzienny Chemioterapii; 🇵🇱 Koszalin, Poland

Szpital Uniwersytecki w Krakowie; Oddzial Kliniczny Onkologii i Poradnia Onkologiczna; 🇵🇱 Kraków, Poland

MRUKMED Lekarz Beata Madej-Mruk i Partner Spolka Partnerska Oddzial nr 1 w Rzeszowie; 🇵🇱 Rzeszow, Poland

Dr. W.M. Szpak Incorporated trading as Rainbow Oncology; 🇿🇦 Durban, South Africa

Hopelands Cancer Centre; 🇿🇦 Hilton, South Africa

Narodowy Instytut Onkologii im. M.Sklodowskiej-Curie; Klinika Nowotworow Piersi i Chirurgii Rekonstr; 🇵🇱 Warszawa, Poland

Medical Oncology Centre of Rosebank; Oncology; 🇿🇦 Johannesburg, South Africa

Richards Bay Oncology Centre; 🇿🇦 KwaZulu Natal, South Africa

Mountain View Oncology; 🇿🇦 Paarl, South Africa

ICO L'Hospitalet; Servicio de oncologia medica; 🇪🇸 L'Hospitalet de Llobregat, Barcelona, Spain

Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia; 🇪🇸 Santiago de Compostela, LA Coruña, Spain

Hospital Universitario de Canarias;servicio de Oncologia; 🇪🇸 La Laguna, Tenerife, Spain

Hospital Universitari Vall d'Hebron; Oncology; 🇪🇸 Barcelona, Spain

Hospital San Pedro De Alcantara; Servicio de Oncologia; 🇪🇸 Caceres, Spain

Hospital General Universitario Gregorio Marañon; Servicio de Oncologia; 🇪🇸 Madrid, Spain

Hospital Ramon y Cajal; Servicio de Oncologia; 🇪🇸 Madrid, Spain

Hospital Universitario 12 de Octubre; Servicio de Oncologia; 🇪🇸 Madrid, Spain

Hospital Regional Universitario Carlos Haya; Servicio de Oncologia; 🇪🇸 Malaga, Spain

Hospital Universitario Virgen de Arrixaca; Servicio de Oncologia; 🇪🇸 Murcia, Spain

Hospital Universitario Virgen Macarena; Servicio de Oncologia; 🇪🇸 Sevilla, Spain

China Medical University Hospital; Surgery; 🇨🇳 Taichung, Taiwan

National Cheng Kung University Hospital; 🇨🇳 Tainan, Taiwan

Taipei Veterans General Hospital; 🇨🇳 Taipei City, Taiwan

Chang Gung Memorial Hosipital at Linkou; 🇨🇳 Taoyuan City, Taiwan

Veterans General Hospital - Taichung; 🇨🇳 Xitun Dist., Taiwan

Maharaj Nakorn Chiang Mai Hospital; Department of Medicine; 🇹🇭 ChiangMai, Thailand

Chulabhorn Hospital; Medical Oncology; 🇹🇭 Lak Si, Thailand

Songklanagarind Hospital; Department of Oncology; 🇹🇭 Songkhla, Thailand

Gulhane Training and Applicaton Hospital; 🇹🇷 Ankara, Turkey

Memorial Ankara Hastanesi; 🇹🇷 Ankara, Turkey

Dicle University Faculty of Medicine; 🇹🇷 Diyarbakir, Turkey

Trakya University Medical Faculty; 🇹🇷 Edirne, Turkey

Medipol Mega Üniversite Hastanesi Göztepe; 🇹🇷 Istanbul, Turkey

Marmara Uni Faculty of Medicine; Medical Oncology; 🇹🇷 Istanbul, Turkey

Ege Uni Medical Faculty Hospital; Oncology Dept; 🇹🇷 Izmir, Turkey

Katip Celebi University Ataturk Training and Research Hospital; Oncology; 🇹🇷 Izmir, Turkey

Goztepe Prof.Dr. Suleyman Yalcin City Hospital; Clinical Oncology; 🇹🇷 Kadiköy, Turkey

Medical Park Seyhan Hospital; Oncology Department; 🇹🇷 Seyhan, Turkey

Hacettepe Uni Medical Faculty Hospital; Oncology Dept; 🇹🇷 Sihhiye/Ankara, Turkey

Basingstoke and North Hampshire Hospital; 🇬🇧 Basingstoke, United Kingdom

Blackpool Victoria Hospital; 🇬🇧 Blackpool, United Kingdom

Dumfries and Galloway Royal Infirmary; 🇬🇧 Dumfries, United Kingdom

Western General Hospital; Clinical Oncology; 🇬🇧 Edinburgh, United Kingdom

Princess Alexandra Hospital; 🇬🇧 Harlow, United Kingdom

St John's Hospital; 🇬🇧 Livingston, United Kingdom

St Bartholomew's Hospital; 🇬🇧 London, United Kingdom

Maidstone & Tonbridge Wells Hospital; Kent Oncology Center; 🇬🇧 Maidstone, United Kingdom

Mount Vernon & Watford Trust Hospital; Dept. of Clinical Oncology; 🇬🇧 Northwood, United Kingdom

Churchill Hospital; Department of Oncology; 🇬🇧 Oxford, United Kingdom

Royal Preston Hosptial; 🇬🇧 Preston, United Kingdom

ROYAL HAMPSHIRE COUNTY HOSPITAL; R&D Office; 🇬🇧 Winchester, United Kingdom